TY - JOUR
T1 - RING finger 138 deregulation distorts NF-кB signaling and facilities colitis switch to aggressive malignancy
AU - Lu, Yalan
AU - Huang, Rong
AU - Ying, Jianming
AU - Li, Xingchen
AU - Jiao, Tao
AU - Guo, Lei
AU - Zhou, Haitao
AU - Wang, Han
AU - Tuersuntuoheti, Amannisa
AU - Liu, Jianmei
AU - Chen, Qichen
AU - Wang, Yanhong
AU - Su, Luying
AU - Guo, Changyuan
AU - Xu, Fu
AU - Wang, Ziyi
AU - Lu, Yan
AU - Li, Kai
AU - Liang, Junbo
AU - Huang, Zhen
AU - Chen, Xiao
AU - Yao, Jinjie
AU - Hu, Hanjie
AU - Cheng, Xiaowen
AU - Wan, Yufeng
AU - Chen, Xinyan
AU - Zhang, Ning
AU - Miao, Shiying
AU - Cai, Jianqiang
AU - Wang, Linfang
AU - Liu, Changzheng
AU - Song, Wei
AU - Zhao, Hong
N1 - Funding Information:
This work was supported by CAMS Innovation Fund for Medical Sciences (CIFMS, 2021-I2M-1-066, 2017-I2M-4-002 to H.Z., 2021-I2M-1-019 to W.S., 2021-1-I2M-014 to C.Z.L.), the National Natural Science Foundation of China (81972311, 82141127 and 81672461 to H.Z., 81672472, and 31970794 to W.S., 81570780 to C.Z.L., 32000586 to K.L.), the Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences (2019PT310026 to H.Z.), and Sanming Project of Medicine in Shenzhen (SZSM202011010 to H.Z.), the National Key Research and Development Program of China (2018YFC1003500 to W.S.), the State Key Laboratory Special fund from the Ministry of Science (2060204 to W.S.), the State Key Project on Infection Diseases of China (2017ZX10201021-007-003 to H.Z.)
© 2022. The Author(s).
PY - 2022/6/13
Y1 - 2022/6/13
N2 - Prolonged activation of nuclear factor (NF)-кB signaling significantly contributes to the development of colorectal cancer (CRC). New therapeutic opportunities are emerging from targeting this distorted cell signaling transduction. Here, we discovered the critical role of RING finger 138 (RNF138) in CRC tumorigenesis through regulating the NF-кB signaling, which is independent of its Ubiquitin-E3 ligase activity involved in DNA damage response. RNF138-/- mice were hyper-susceptible to the switch from colitis to aggressive malignancy, which coincided with sustained aberrant NF-кB signaling in the colonic cells. Furthermore, RNF138 suppresses the activation of NF-кB signaling pathway through preventing the translocation of NIK and IKK-Beta Binding Protein (NIBP) to the cytoplasm, which requires the ubiquitin interaction motif (UIM) domain. More importantly, we uncovered a significant correlation between poor prognosis and the downregulation of RNF138 associated with reinforced NF-кB signaling in clinical settings, raising the possibility of RNF138 dysregulation as an indicator for the therapeutic intervention targeting NF-кB signaling. Using the xenograft models built upon either RNF138-dificient CRC cells or the cells derived from the RNF138-dysregulated CRC patients, we demonstrated that the inhibition of NF-кB signaling effectively hampered tumor growth. Overall, our work defined the pathogenic role of aberrant NF-кB signaling due to RNF138 downregulation in the cascade events from the colitis switch to colonic neoplastic transformation and progression, and also highlights the possibility of targeting the NF-кB signaling in treating specific subtypes of CRC indicated by RNF138-ablation.
AB - Prolonged activation of nuclear factor (NF)-кB signaling significantly contributes to the development of colorectal cancer (CRC). New therapeutic opportunities are emerging from targeting this distorted cell signaling transduction. Here, we discovered the critical role of RING finger 138 (RNF138) in CRC tumorigenesis through regulating the NF-кB signaling, which is independent of its Ubiquitin-E3 ligase activity involved in DNA damage response. RNF138-/- mice were hyper-susceptible to the switch from colitis to aggressive malignancy, which coincided with sustained aberrant NF-кB signaling in the colonic cells. Furthermore, RNF138 suppresses the activation of NF-кB signaling pathway through preventing the translocation of NIK and IKK-Beta Binding Protein (NIBP) to the cytoplasm, which requires the ubiquitin interaction motif (UIM) domain. More importantly, we uncovered a significant correlation between poor prognosis and the downregulation of RNF138 associated with reinforced NF-кB signaling in clinical settings, raising the possibility of RNF138 dysregulation as an indicator for the therapeutic intervention targeting NF-кB signaling. Using the xenograft models built upon either RNF138-dificient CRC cells or the cells derived from the RNF138-dysregulated CRC patients, we demonstrated that the inhibition of NF-кB signaling effectively hampered tumor growth. Overall, our work defined the pathogenic role of aberrant NF-кB signaling due to RNF138 downregulation in the cascade events from the colitis switch to colonic neoplastic transformation and progression, and also highlights the possibility of targeting the NF-кB signaling in treating specific subtypes of CRC indicated by RNF138-ablation.
KW - Animals
KW - Cell Transformation, Neoplastic
KW - Colitis/genetics
KW - Humans
KW - Mice
KW - NF-kappa B/genetics
KW - Signal Transduction/genetics
KW - Ubiquitin-Protein Ligases/genetics
KW - Ubiquitins
UR - http://www.scopus.com/inward/record.url?scp=85131810748&partnerID=8YFLogxK
U2 - 10.1038/s41392-022-00985-1
DO - 10.1038/s41392-022-00985-1
M3 - Article
C2 - 35697692
SN - 2059-3635
VL - 7
JO - Signal Transduction and Targeted Therapy
JF - Signal Transduction and Targeted Therapy
M1 - 185
ER -